Stanley Capital Partners, the European and US-focused mid-market private equity firm, agreed to acquire the drug safety unit of Nordic and Astorg-backed Clario, a provider of endpoint technology solutions for clinical trials. Financial terms were not disclosed. "Our investment in DSS follows several years of deep thematic research into the pharmaceuticals outsourcing sector and marks our second acquisition at Stanley Capital as a result of that work. DSS uses its unique proprietary technology to improve quality and efficiency for its clients – a capability that will be enhanced and accelerated by our own S-Labs automation capability, organic investment and future acquisitions. We believe DSS is a strong platform with which to build a tech-enabled data-led services leader in the PV market and we look forward to working with Humaira and her team to deliver that ambition," Simon Cottle, Stanley Capital Partner.